GPC-3 CAR-T for advanced liver cancer
Part of Cancer clinical trials.
This trial tests CAR-T cell therapy (immune cells changed to target GPC-3) for advanced hepatocellular carcinoma, especially when standard treatments no longer work or you cannot tolerate them. If eligible, the goal is to shrink tumors and help you live longer with improved cancer control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 70 years old
- You have advanced liver cancer that cannot be removed or treated locally, and it has progressed or you could not tolerate standard treatment
- Your tumor tissue test is positive for GPC-3
- Your liver function is fairly preserved (Child-Pugh A) and your performance status is 0 to 1
- You have at least one measurable tumor spot on scans (size limits) and you’re expected to live more than 12 weeks
- You had to stop PD-1 antibody treatment more than 28 days ago due to it not working or being intolerable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
This Phase 1 study tests a personalized immune-cell treatment (CAR T cells) for advanced liver cancer that has the GPC3 protein. It aims to see whether these engineered cells can find and kill cancer cells safely and help shrink the cancer.
This trial tests a new cell therapy called Super CAR-T for people with advanced liver cancer that has GPC3 protein. It aims to see if the treatment is safe and effective. You may be eligible if your cancer has not responded to or stopped working on at least two standard treatments.
This trial tests a new cell therapy made from natural killer (NK) cells that are engineered to attack two targets (GPC3 and B7-H3) found on liver cancer cells. It may be an option for people with advanced liver cancer who have already tried standard treatments.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
This trial tests a new treatment called CAR-T cells that are designed to find and attack liver cancer cells with a specific marker (GPC3). If you have advanced hepatocellular carcinoma (liver cancer) that has not responded to standard treatments, this study may be an option to explore.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.